/VSTM
VSTM Stock - Verastem, Inc.
Healthcare|BiotechnologyNASDAQ
$7.76+0.13%
+$0.01 (+0.13%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.42
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+80.4%upside
Target: $14.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VSTM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.68 – $7.84
TARGET (TP)$14.00
STOP LOSS$7.14
RISK/REWARD1:10.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.41
52W High$11.25
52W Low$3.46
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.00M | N/A | $2.60M | $2.05M | $88.52M |
| Gross Profit | $10.00M | N/A | $2.60M | $2.05M | $54.77M |
| Gross Margin | 100.0% | N/A | 100.0% | 100.0% | 61.9% |
| Operating Income | $-114,956,000 | $-92,084,000 | $-72,937,000 | $-61,409,000 | $-49,360,000 |
| Net Income | $-130,637,000 | $-87,367,000 | $-73,812,000 | $-71,200,000 | $-67,726,000 |
| Net Margin | -1306.4% | N/A | -2843.3% | -3468.1% | -76.5% |
| EPS | $-3.66 | $-3.96 | $-4.57 | $-4.92 | $-5.28 |
Company Overview
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish0 Neutral/Bearish
Price Targets
$16
Average Target
↑ 103.6% Upside
Now
$5
Low
$16
Average
$36
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 16th 2025 | Cantor Fitzgerald | Resumed | Overweight | - |
| April 10th 2025 | Jefferies | Initiation | Buy | $15 |
| March 24th 2025 | H.C. Wainwright | Reiterated | Buy | $10← $7 |
| December 31st 2024 | BTIG Research | Reiterated | Buy | $20← $13 |
| September 30th 2024 | Guggenheim | Initiation | Buy | $13 |
| November 21st 2023 | BTIG Research | Resumed | Buy | $27 |
| September 27th 2023 | B. Riley Securities | Initiation | Buy | $21 |
| June 15th 2023 | Mizuho | Upgrade | Buy | $36← $24 |
| September 7th 2022 | Alliance Global Partners | Resumed | Buy | $6 |
| April 29th 2022 | Cantor Fitzgerald | Resumed | Overweight | $5← $6 |
| April 14th 2022 | RBC Capital Mkts | Initiation | Outperform | $5 |
Earnings History & Surprises
VSTMBeat Rate
33%
Last 18 quarters
Avg Surprise
-70.6%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-1.35
Q4 2025
EPS Surprise History
Q1 24
-24.4%
$-1.02vs$-0.82
Q2 24
-8.6%
$-1.26vs$-1.16
Q3 24
+70.8%
$-0.31vs$-1.06
Q4 24
+15.5%
$-0.60vs$-0.71
Q1 25
-64.2%
$-1.33vs$-0.81
Q2 25
-33.3%
$-0.96vs$-0.72
Q3 25
+54.1%
$-0.39vs$-0.85
Q4 25
-164.7%
$-1.35vs$-0.51
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.45 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.51 | $-1.35 | -164.7% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.85 | $-0.39 | +54.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.72 | $-0.96 | -33.3% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.81 | $-1.33 | -64.2% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.71 | $-0.60 | +15.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.06 | $-0.31 | +70.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-1.16 | $-1.26 | -8.6% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.82 | $-1.02 | -24.4% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.92 | $-0.75 | +18.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.13 | $-1.37 | -21.2% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-1.08 | $-0.96 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $0.10 | $-0.96 | -1060.0% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-1.44 | $-1.08 | +25.0% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-1.32 | $-1.44 | -9.1% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.96 | $-1.08 | -12.5% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.96 | $-1.08 | -12.5% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-1.08 | $-1.56 | -44.4% | ✗ MISS |
Q3 2021 | Aug 2, 2021 | $-1.08 | $-1.20 | -11.1% | ✗ MISS |
Latest News
Verastem Appoints John Johnson As Chairman Of The Board; Co. Announces That It Has Completed The Additional Patient Enrollment For Ramp 301, Its International Phase 3 Confirmatory Trial In Recurrent LGSOC
📈 PositiveBenzinga•Dec 15, 2025, 09:07 PM
Verastem Oncology Prices 8,543,794 Shares At $7.25 In $90M Public Offering With 3,870,000 Pre-Funded Warrants At $7.2499
➖ NeutralBenzinga•Nov 14, 2025, 06:54 AM
Verastem shares are trading lower after the company announced a common stock offering.
📉 NegativeBenzinga•Nov 13, 2025, 09:32 PM
Verastem Oncology Announces Common Stock Offering; Terms Not Disclosed
📉 NegativeBenzinga•Nov 13, 2025, 09:10 PM
Verastem Oncology drops despite Q3 double beat
📉 NegativeSeeking Alpha•Nov 4, 2025, 05:12 PM
Verastem shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 4, 2025, 02:18 PM
Verastem Q3 Adj. EPS $(0.54) Beats $(0.64) Estimate, Sales $11.242M Beat $5.659M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 12:31 PM
Verastem shares are trading higher after the company reported preliminary Phase 1/2a clinical trial data showing no dose-limiting toxicities and initiated enrollment for combination therapy.
📈 PositiveBenzinga•Oct 23, 2025, 08:32 PM
Verastem Reveals Preliminary Data From The First Two Dose Levels In Its Ongoing Phase 1/2a Clinical Trial Evaluating VS-7375; First Two Monotherapy Dose Levels Cleared, With No Dose-limiting Toxicities Reported; Enrollment Initiated For VS-7375 In Combination With Cetuximab In Patients With Advanced KRAS G12D Mutant Solid Tumors, Including Colorectal Cancer
📈 PositiveBenzinga•Oct 23, 2025, 08:08 PM
Verastem Oncology shares are trading lower. The company announced updated efficacy and safety data from partner GenFleet Therapeutics' Phase 1/2 monotherapy study in China of GFH375.
📉 NegativeBenzinga•Oct 20, 2025, 04:44 PM
Reported Sunday, Verastem And GenFleet Report 41% Overall Response Rate, 91.5% Tumor Reduction, And 96.7% Disease Control Rate With GFH375 (VS-7375) Monotherapy In Advanced KRAS G12D Mutant Pancreatic Cancer At 600 mg Dose
📈 PositiveBenzinga•Oct 20, 2025, 07:42 AM
Cantor Fitzgerald Assumes Verastem at Overweight
📈 PositiveBenzinga•Oct 16, 2025, 01:17 PM
BTIG Reiterates Buy on Verastem, Maintains $20 Price Target
📈 PositiveBenzinga•Sep 9, 2025, 11:13 AM
Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline
📈 PositiveSeeking Alpha•Aug 8, 2025, 06:49 PM
Verastem Oncology rises on $75M private placement
📈 PositiveSeeking Alpha•Apr 25, 2025, 01:04 PM
Frequently Asked Questions about VSTM
What is VSTM's current stock price?
Verastem, Inc. (VSTM) is currently trading at $7.76 per share. The stock has moved +0.13% today.
What is the analyst price target for VSTM?
The average analyst price target for VSTM is $14.00, based on 1 analyst.
What sector is Verastem, Inc. in?
Verastem, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VSTM's market cap?
Verastem, Inc. has a market capitalization of $0.47 billion, making it a small-cap company.
Does VSTM pay dividends?
No, Verastem, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to VSTM for comparison